1. Home
  2. RCUS vs HYT Comparison

RCUS vs HYT Comparison

Compare RCUS & HYT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RCUS
    SELLHOLDBUYas of 8 hours ago
  • HYT
    SELLHOLDBUYas of 8 hours ago
  • Stock Information
  • Founded
  • RCUS 2015
  • HYT 2003
  • Country
  • RCUS United States
  • HYT United States
  • Employees
  • RCUS N/A
  • HYT N/A
  • Industry
  • RCUS Biotechnology: Pharmaceutical Preparations
  • HYT Finance Companies
  • Sector
  • RCUS Health Care
  • HYT Finance
  • Exchange
  • RCUS Nasdaq
  • HYT Nasdaq
  • Market Cap
  • RCUS 1.4B
  • HYT 1.4B
  • IPO Year
  • RCUS 2018
  • HYT N/A
  • Fundamental
  • Price
  • RCUS $13.40
  • HYT $9.78
  • Analyst Decision
  • RCUS Buy
  • HYT
  • Analyst Count
  • RCUS 12
  • HYT 0
  • Target Price
  • RCUS $34.50
  • HYT N/A
  • AVG Volume (30 Days)
  • RCUS 604.6K
  • HYT 443.0K
  • Earning Date
  • RCUS 02-19-2025
  • HYT 01-01-0001
  • Dividend Yield
  • RCUS N/A
  • HYT 9.61%
  • EPS Growth
  • RCUS N/A
  • HYT N/A
  • EPS
  • RCUS N/A
  • HYT N/A
  • Revenue
  • RCUS $263,000,000.00
  • HYT N/A
  • Revenue This Year
  • RCUS $127.65
  • HYT N/A
  • Revenue Next Year
  • RCUS N/A
  • HYT N/A
  • P/E Ratio
  • RCUS N/A
  • HYT N/A
  • Revenue Growth
  • RCUS 119.17
  • HYT N/A
  • 52 Week Low
  • RCUS $13.40
  • HYT $8.18
  • 52 Week High
  • RCUS $20.31
  • HYT $9.91
  • Technical
  • Relative Strength Index (RSI)
  • RCUS 32.67
  • HYT 46.78
  • Support Level
  • RCUS $13.81
  • HYT $9.72
  • Resistance Level
  • RCUS $14.45
  • HYT $9.80
  • Average True Range (ATR)
  • RCUS 0.58
  • HYT 0.07
  • MACD
  • RCUS -0.09
  • HYT 0.00
  • Stochastic Oscillator
  • RCUS 0.00
  • HYT 37.50

Stock Price Comparison Chart: RCUS vs HYT

RCUS
HYT
AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober202505101520253035404550RCUS VS HYT

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

About HYT Blackrock Corporate High Yield Fund Inc.

BlackRock Corporate High Yield Fund Inc is a diversified, closed-end management investment company. Its investment objective is to provide shareholders with current income and capital appreciation. The trust's secondary investment objective is to provide shareholders with capital appreciation. It seeks to achieve its objectives by investing in a diversified portfolio of fixed-income securities.

Share on Social Networks:

0

By browsing this website, you accept our Privacy Policy & Terms of Use